MedTrace Logo

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

NCT04982068 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-04-19

No results posted yet for this study

Summary

The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and preliminary immunogenicity of 202-CoV at multiple dose levels, administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age and above.

Conditions

Interventions

BIOLOGICAL

202-CoV low adjuvant dose

standard dose of 202-CoV with low dose CpG / alum adjuvant

BIOLOGICAL

202-CoV low antigen dose

low dose 202-CoV with CpG / alum adjuvant

BIOLOGICAL

202-CoV standard dose

standard dose 202-CoV with CpG / alum adjuvant

OTHER

Placebo

Normal saline solution

Sponsors & Collaborators

  • Walvax Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • Shanghai Zerun Biotechnology Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-12
Primary Completion
2021-10-31
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04982068 on ClinicalTrials.gov